ASCENDIS PHARMA BONE
PharmaASCENDIS PHARMA BONE is a pharmaceutical company focused on Metabolic. Key products include YORVIPATH.
FDA Novel Drug Designations
(2024)See 1 novel approval →
ASCENDIS PHARMA BONE's Key Drugs
ASCENDIS PHARMA BONE's core commercial portfolio centers on YORVIPATH, spanning Metabolic — its most strategically important drugs approved in the last 15 years.
ASCENDIS PHARMA BONE's Recent FDA Approvals
ASCENDIS PHARMA BONE secured 1 new FDA approval for novel drugs (NDA/BLA) in the last two years.
ASCENDIS PHARMA BONE's Therapeutic Areas
ASCENDIS PHARMA BONE's approved drugs and pipeline span 1 therapeutic area, led by Metabolic, across 0 biologic and 1 small-molecule drug. Weighted by commercial stage — approved drugs count most, then late-stage trials.
ASCENDIS PHARMA BONE's Top Competitors
ASCENDIS PHARMA BONE's closest competitors by therapeutic-area and drug-target overlap include Merck, Baxter, and Johnson & Johnson. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.
ASCENDIS PHARMA BONE Pipeline Snapshot
ASCENDIS PHARMA BONE has 2 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 0 Phase 2 and 0 Phase 1.
Pro Intelligence Preview
Deep insights for investors and analysts
Revenue Insights
- • YORVIPATH leads revenue
- • Drug-level revenue analysis
Trial Catalysts
- • Metabolic pipeline focus
- • Phase 3 readout tracking
Patent Risk
- • Patent expiration timeline
- • Revenue at risk analysis
Compare Companies
- • Side-by-side pipeline analysis
- • Revenue & market share comparison
Revenue forecasts • Trial milestones • Patent risk modeling
Active (1)
Discontinued (0)
Company Info
- First Approval
- 2024-08-09
- Latest
- 2025-10-16
- Applications
- 1